

Clinical Trial Protocol

Iranian Registry of Clinical Trials

03 Jul 2026

The effect of sodium butyrate supplementation on serum oxidative stress indices and gene expression level of pyroptosis related inflammatory factors in type 2 diabetic patients: A randomized, double-blind, placebo-controlled trial

Protocol summary

Study aim

This study will be done with the aim of investigating the effect of sodium butyrate supplementation on serum oxidative stress indices and gene expression level of pyroptosis related inflammatory factors in type 2 diabetic patients.

Design

In this double-blind randomized placebo-controlled parallel group clinical trial, 42 type 2 diabetic patients of both sexes will be randomly divided into 2 groups of 21 individuals.

Settings and conduct

The study will be conducted in the Nutrition Research Center of Tabriz University of Medical Sciences. Patients will be randomly assigned into 2 groups. The questionnaires of general information will be completed. After random allocation each patient will receive proprietary supplement for 6 weeks. Sodium butyrate and placebo packs will be encoded by the person responsible for preparation; investigators and patients will be blinded to the type of the supplement each group receives. Fasting blood samples will be collected at baseline and at the end of the study.

Participants/Inclusion and exclusion criteria

Major eligibility criteria: Ages between 30 to 50 years; Diagnosis of type 2 diabetes; BMI between 27 to 35 kg/m². Exclusion criteria: chronic diseases; Kidney, liver and thyroid disorders; Rheumatic Diseases; Inflammatory diseases; Insulin injection, taking estrogenic drugs, progesterone & corticosteroids; Taking supplements, and antibiotics; Smoking; Pregnancy; lactation; menopause;

Intervention groups

Group 1 will receive sodium butyrate capsules (BodyBio) for 6 weeks at a daily dose of 600 mg in the form of capsules of 100 mg with food. Group 2, as a control group, will use 6 starch capsules daily as placebo.

Main outcome variables

Glycemic indexes; lipid profile; expression of TLR-4, NLRP3, ASC, Caspase-1, IL-1 β , IL-18; glutathione peroxidase(GPx); Nitric oxide(NO) will be evaluated before and after the supplementation.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20090609002017N33**

Registration date: **2019-04-06, 1398/01/17**

Registration timing: **registered_while_recruiting**

Last update: **2019-04-06, 1398/01/17**

Update count: **0**

Registration date

2019-04-06, 1398/01/17

Registrant information

Name

Alireza Ostadrahimi

Name of organization / entity

Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1335 7580

Email address

ostadrahimi@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-03-25, 1398/01/05
Expected recruitment end date
2019-05-15, 1398/02/25
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title

The effect of sodium butyrate supplementation on serum oxidative stress indices and gene expression level of pyroptosis related inflammatory factors in type 2 diabetic patients: A randomized, double-blind, placebo-controlled trial

Public title

Effect of sodium butyrate in prevention and treatment of type 2 diabetes

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Willingness to participate in the study Ages between 30 to 50 years (both sexes) Diagnosis of type 2 diabetes Body mass index (BMI) between 27 to 35 kg/m² People who control their diabetes just by using blood glucose lowering tablets.

Exclusion criteria:

Unwillingness to participate in the study Chronic diseases such as cardiovascular disorders and ... Kidney, liver and thyroid disorders Rheumatic Diseases Inflammatory diseases of the gastrointestinal tract or malabsorption, such as sprue and crows Insulin injection, taking estrogenic drugs, progesterone & corticosteroids Taking vitamin supplements; minerals; omega-3 and antibiotics for three weeks before the study Changes in diet and physical activity Smoking Having certain physiological conditions like pregnancy and lactation and menopause

Age

From **30 years** old to **50 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **42**

Randomization (investigator's opinion)

Randomized

Randomization description

Samples will be assigned to intervention and control groups by random blocking.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, investigator and participants will be unaware of the type of supplementation (sodium butyrate or placebo). The person responsible for the preparation of capsules' packs (a person completely

unrelated to the study) will be asked to assign a code to each of the two packages (sodium butyrate and placebo), and to keep the codes up to the end of the study and data analysis.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tabriz University of Medical Sciences

Street address

3rd. Floor, Central Bldg. No.2, Golgasht st., Azadi Ave.

City

Tabriz

Province

East Azarbaijan

Postal code

5166614776

Approval date

2019-03-11, 1397/12/20

Ethics committee reference number

IR.TBZMED.REC.1397.1036

Health conditions studied

1

Description of health condition studied

Diabetes mellitus Type 2

ICD-10 code

E10, E11,

ICD-10 code description

Diabetes

Primary outcomes

1

Description

TLR-4 expression

Timepoint

Before & after the intervention

Method of measurement

Real-time PCR

2

Description

NLRP3 expression

Timepoint

Before & after the intervention
Method of measurement
Real-time PCR

3

Description
Caspase-1 expression
Timepoint
Before & after the intervention
Method of measurement
Real-time PCR

4

Description
ASC expression
Timepoint
Before & after the intervention
Method of measurement
Real-time PCR

5

Description
IL-1 β expression
Timepoint
Before & after the intervention
Method of measurement
Real-time PCR

6

Description
IL-18 expression
Timepoint
Before & after the intervention
Method of measurement
Real-time PCR

7

Description
Glutathion Peroxidase (GPx)
Timepoint
Before & after the intervention
Method of measurement
Kit

8

Description
Nitric Oxide (NO)
Timepoint
Before & after the intervention
Method of measurement
Kit

9

Description
Fasting Blood Glucose
Timepoint
Before & after the intervention

Method of measurement
Enzymatic assay

10

Description
Fasting Insulin
Timepoint
Before & after the intervention
Method of measurement
ELISA

11

Description
HbA1c
Timepoint
Before & after the intervention
Method of measurement
Kit

12

Description
HOMA-IR
Timepoint
Before & after the intervention
Method of measurement
HOMA-IR formula: [fasting insulin (μ U/ml)*fasting glucose (mg/dL)]/ 405

13

Description
Triglyceride
Timepoint
Before & after the intervention
Method of measurement
Enzymatic method

14

Description
HDL-Cholesterol
Timepoint
Before & after the intervention
Method of measurement
Enzymatic method

15

Description
Total Cholesterol
Timepoint
Before & after the intervention
Method of measurement
Enzymatic method

16

Description
LDL-Cholesterol
Timepoint
Before & after the intervention

Method of measurement

Friedewald's formula: $LDL = TC - [HDL + (TG/5)]$

Secondary outcomes**1****Description**

Systolic Blood Pressure

Timepoint

Before & after the intervention

Method of measurement

Digital barometer

2**Description**

Diastolic Blood Pressure

Timepoint

Before & after the intervention

Method of measurement

Digital barometer

3**Description**

Energy and macro-nutrient intake

Timepoint

Before & after the intervention

Method of measurement

Questionnaire (3 days dietary record)

4**Description**

Weight

Timepoint

Before & after the intervention

Method of measurement

scale

5**Description**

Body Mass Index

Timepoint

Before & after the intervention

Method of measurement

BMI formula

6**Description**

Waist circumference

Timepoint

Before & after the intervention

Method of measurement

Nonelastic flexible tape

7**Description**

Hip circumferences

Timepoint

Before & after the intervention

Method of measurement

Nonelastic flexible tape

8**Description**

Waist to Hip Ratio (WHR)

Timepoint

Before & after the intervention

Method of measurement

Calculation

Intervention groups**1****Description**

Group 1 will receive sodium butyrate capsules (BodyBio) for 6 weeks at a daily dose of 600 mg in the form of capsules of 100 mg with meals.

Category

Treatment - Drugs

2**Description**

Control group: Group 2 will use starch capsule as placebo for 6 weeks at a daily dose of 6 capsule with meals.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Roohzende Health and Therapeutic Center no.2

Full name of responsible person

Neda Roshanravan

Street address

Emam Khomeini St.

City

Shabestar

Province

East Azarbaijan

Postal code

5381855785

Phone

+98 41 3335 7580

Email

neda.roshanravan10@gmail.com

Web page address**2****Recruitment center****Name of recruitment center**

AZAR Cohort recruitment center (Khamaneh Hospital's outpatient clinic)

Full name of responsible person

Alireza Ostadrahimi

Street address

Sheikh Mohammad Khiabani st.

City

Shabestar

Province

East Azarbaijan

Postal code

Phone

+98 41 3335 7580

Email

ostadrahimi@tbzmed.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**Nutrition Research Center, Tabriz University of
Medical Science**Full name of responsible person**

Alireza Ostadrahimi

Street address5th Floor, Nutrition Faculty Bldg., Attar Neyshaburi st.,
Golgasht ave.**City**

Tabriz

Province

East Azarbaijan

Postal code

5166614711

Phone

+98 41 3335 2295

Email

ostadrahimi@tbzmed.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding sourceNutrition Research Center, Tabriz University of Medical
Science**Proportion provided by this source**

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Zeinab Khosravi

Position

MSc student in Nutrition

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street addressFaculty of Nutrition, Tabriz University of Medical
Science, Attar Neyshaburi st., Golgasht ave.**City**

Tabriz

Province

East Azarbaijan

Postal code

5166614711

Phone

+98 41 3335 7580

Email

z.khosravi71@yahoo.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Alireza Ostadrahimi

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street addressFaculty of Nutrition, Tabriz University of Medical
Science, Attar Neyshaburi st., Golgasht ave.**City**

Tabriz

Province

East Azarbaijan

Postal code

5166614711

Phone

+98 41 3335 2295

Email

ostadrahimi@tbzmed.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Zeinab Khosravi

Position

MSc student in Nutrition

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Faculty of Nutrition, Tabriz University of Medical Science, Attar Neyshaburi st., Golgasht ave.

City

Tabriz

Province

East Azarbaijan

Postal code

5166614711

Phone

+98 41 3335 7580

Email

z.khosravi71@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

Individual participant data that underlie the outcomes reported in this article, after deidentification (text, tables, figures, and appendices), Study Protocol, Statistical Analysis Plan, Clinical Study Report

When the data will become available and for how long

Beginning 6 months and ending 2 years following article publication

To whom data/document is available

Researchers who provide a methodologically sound proposal.

Under which criteria data/document could be used

The datasets are available from the corresponding author on reasonable request and to achieve aims in the approved proposal.

From where data/document is obtainable

Proposals should be directed to corresponding author.

What processes are involved for a request to access data/document

All data requests should be submitted to the corresponding author for consideration. To gain access, data requestors will need to sign a data access agreement.

Comments